Track IDEXX Laboratories, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

IDEXX Laboratories, Inc. IDXX Open IDEXX Laboratories, Inc. in new tab

569.55 USD
P/E
43.48
EPS
13.10
P/B
28.28
ROE
66.20
Beta
1.72
Target Price
742.54 USD
IDEXX Laboratories, Inc. logo

IDEXX Laboratories, Inc.

🧾 Earnings Recap – Q3 2025

IDEXX Laboratories reported robust Q3 2025 results with a 13% rise in revenue, bolstered by strong performance in their Companion Animal Group (CAG) business despite some headwinds from clinical visit declines.

  • Revenue increased to $1.080 billion, a 13% year-over-year jump, with organic growth at 12%.
  • CAG Diagnostics recurring revenues grew 10% organically, driven by a significant rise in premium instrument placements, including over 1,750 InVue Dx analyzers resulting in 71% growth in instrument revenues.
  • Updated full-year guidance reflects increased revenue expectations of $4.270-$4.300 billion and EPS outlook raised to $12.81-$13.01, indicating strong operational momentum despite macro challenges.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 7, 2026
P/E43.48
EPS13.10
Book Value20.14
Price to Book28.28
Debt/Equity60.83
% Insiders0.707%
Growth
Revenue Growth0.14%
Earnings Growth0.18%
Estimates
Forward P/E34.68
Forward EPS16.42
Target Mean Price742.54

DCF Valuation

Tweak assumptions to recompute fair value for IDEXX Laboratories, Inc. (IDXX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

IDEXX Laboratories, Inc. Logo IDEXX Laboratories, Inc. Analysis (IDXX)

United States Health Care Official Website Stock

Is IDEXX Laboratories, Inc. a good investment? IDEXX Laboratories, Inc. (IDXX) is currently trading at 569.55 USD. Market analysts have a consensus price target of 742.54 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 43.48. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: IDEXX Laboratories, Inc. is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is 16.42.

Investor FAQ

Does IDEXX Laboratories, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is IDEXX Laboratories, Inc.?

IDEXX Laboratories, Inc. is classified as a Stock. You can compare it against 7 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of 13.10.

Company Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Exchange Ticker
MEX (Mexico) IDXX.MX
VIE (Austria) IDXX.VI
SAO (Brazil) I1DX34.SA
GER (Germany) IX1.DE
FRA (Germany) IX1.F
LSE (United Kingdom) 0J8P.L
NMS (United States) IDXX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Nov. 27, 2007 2.000000
June 16, 2015 2.000000
June 6, 1995 2.000000
Oct. 4, 1993 2.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion